维奈克拉治疗多发性骨髓瘤:临床试验外的真实世界结局
中位既往治疗线数为6,95%对免疫调节药物和蛋白酶体抑制剂难治。总缓解率44%,中位无进展生存期5.8个月,中位总生存期28.4个月;t(11;14)与更优的无进展生存期和总生存期相关。
要点
- 维奈克拉在重度经治的复发/难治骨髓瘤中总缓解率44%,中位缓解持续时间13.6个月。
- t(11;14)患者的中位无进展生存期显著优于无t(11;14)者(9.7 vs 4.2个月,p=0.019)。
- 未观察到肿瘤溶解综合征,维奈克拉在临床试验外使用安全性可控。
核心结论
- 维奈克拉在重度经治的复发/难治多发性骨髓瘤患者中显示出令人鼓舞的活性,尤其是t(11;14)人群。
研究设计与样本
- 数据截止日期为2020年8月6日;42例(75%)携带t(11;14)。
- 中位既往治疗线数为6(范围1-15),14%的患者接受过≥10线治疗。
主要发现
- 52例可评估患者的总缓解率为44%。
- 中位至最佳缓解时间为2个月,中位缓解持续时间为13.6个月。
- 全队列中位无进展生存期为5.8个月(95%CI 4.9-10.3),中位总生存期为28.4个月(95%CI 14.6-未达到)。
- t(11;14)与改善的无进展生存期相关(中位9.7 vs 4.2个月,p=0.019)和总生存期相关(中位未达到 vs 10.8个月,p=0.015)。
- 无患者发生肿瘤溶解综合征。
关键数值与推荐
- 维奈克拉作为单药或双药方案(55%,n=31,与地塞米松联合)使用,45%的患者使用三药或四药方案。
- t(11;14)患者中位无进展生存期9.7个月,无t(11;14)者4.2个月(p=0.019)。
- t(11;14)患者中位总生存期未达到,无t(11;14)者10.8个月(p=0.015)。
临床怎么用
- 对于重度经治的复发/难治多发性骨髓瘤患者,尤其是t(11;14)阳性者,维奈克拉可作为治疗选择。
- 维奈克拉在临床试验外使用未发生肿瘤溶解综合征,支持其安全性。
局限性
- 回顾性研究,样本量较小(56例),可能存在选择偏倚。
- 数据来自单中心(Mayo Clinic),结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) remains an incurable disease despite incorporation of novel agents. Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor is approved for some hematologic malignancies but not yet for MM, although clinical trials have shown efficacy in patients with MM, particularly those harboring t(11;14). We reviewed the medical records of relapsed and/or refractory MM patients to study the efficacy and safety of venetoclax used outside of clinical trials at Mayo Clinic between December, 2016 and March, 2019. The data cut-off date was August 06, 2020. We identified 56 patients of whom 42 (75%) harbored t(11;14). The median number of prior therapies was six (range 1-15) and 14% of patients had received ≥10 prior lines of therapy. Fifty-three (95%) patients were refractory to an immunomodulatory drug and proteasome inhibitor. Venetoclax was used as monotherapy or doublet, in combination with dexamethasone in 55% (n = 31) and a triplet or quadruplet in 45% of patients. No patient experienced tumor lysis syndrome. Overall response rate in 52 evaluable patients was 44%. The median time to best response was 2 months and median duration of response was 13.6 months. The median PFS for the entire cohort was 5.8 (95% CI 4.9-10.3) months and median OS was 28.4 (95% CI 14.6-not reached) months. The presence of t(11;14) was associated with improved PFS (median 9.7 months vs. 4.2 months, p = 0.019) and OS (median not reached vs. 10.8 9 months, p = 0.015). Venetoclax demonstrates encouraging activity in heavily-treated patients with relapsed/refractory MM, particularly the t(11;14) patient-population.
引用
- Sidiqi MH, Al Saleh AS, Kumar SK, et al. Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. Am J Hematol. 2021. PMID: 34115387. doi:10.1002/ajh.26269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。